All Episodes
The Lancet Oncology in conversation with — 76 episodes
Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
Ali Landman on the European Congress of Radiology 2026
Kayleigh Bhangdia on breast cancer GBD study 2023
Dylan Graetz and Erica Kaye on qualitative research in oncology
Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers
Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3
Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission
Matthias Preusser on the phase 2 TUXEDO-3 trial
Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer
Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas
Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer
Abdalla Awidi on cancer control in the Middle East
ASCO 2025 Debrief
Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial)
Richard Bryant on transperineal vs transrectal biopsy for prostate cancer
Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)
Ariana Znaor on cancer surveillance in the Eastern Mediterranean region
Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials
Yannick Romero on the changing landscape of national cancer control plans
M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries
Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma
Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination
May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics
Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)
Emmy Boerrigter on dose selection of novel anticancer drugs
Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations
Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment
James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean
Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials
Maria Kyrgiou on innovations in gynaecological cancers and global disparities
Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers
Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer
Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma
Neerja Bhatla on a new quadrivalent HPV vaccine
Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery
Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma
Wanda Cui on measuring ovarian toxicity
Ticiana Leal on Tumour Treating Fields
Xuesong Han on cancer diagnosis during the COVID-19 pandemic in the USA
Carlos Fernández de Larrea and Damian Green on BCMA CAR T cells in multiple myeloma
Madeline Pe on the SISAQOL initiative
Kadia Petricca and Joyce Kambugu on access to essential cancer medicines for children
Mark Lythgoe on UK oncology drug approval after Brexit
Janet Brown on the phase 2/3 STAR trial
Valerie Speirs on biomarkers in male breast cancer
Sameer Bakhshi on sex disparities in childhood cancer in India
Shankar Siva on radiotherapy for primary renal cell carcinoma
Mark Lawler and Richard Sullivan on the European Groundshot
Samar Alhomoud on challenges for cancer control in the Gulf region
Inge Marie Svane on mRNA vaccines for cancer treatment
Eline Giraud and Elise Smolders on QT interval prolongation potential of anticancer
Ignace Vergote and Maria Kyrgiou on gynaecological cancers
David J Pinato on SARS-CoV-2 omicron outcomes among patients with cancer
Wilfred Ngwa, Beatrice Wiafe-Addai, and David Kerr on cancer in sub-Saharan Africa
Georgios Lyratzopoulos on emergency presentation
Lisa Iezzoni on disabilities and cancer, and Jordan Marchak on mental health problems in young cancer survivors
Rosie Bradley on early-stage breast cancer treatment
Yi-Long Wu and Caicun Zhou on non-small-cell lung cancer
Rebecca Fitzgerald on Barrett’s oesophagus surveillance
Elysia Alvarez on adolescent and young adult cancer
Aju Mathew on cancer care in India
David Pinato on cancer patients who recovered from SARS-CoV-2 infection
James Glasbey on the effect of lockdowns on cancer surgery
Manju Sengar and Christopher Booth on essential cancer drugs
Susannah Stanway, Richard Cowan, Danielle Rodin, and Miriam Mutebi on helping with cancer control in LMICs
Harriet Rumgay on the burden of cancer attributable to alcohol
Rafael Cardoso and Hermann Brenner on colorectal cancer
Takayuki Yoshino on the DESTINY-CRC01 trial
Roberto Orecchia on the ELIOT trial
Hedvig Hricak, Andrew Scott, Rifat Atun, and May Abdel-Wahab on nuclear medicine
Ariana Znaor on breast and cervical cancer in the former Soviet Union
Sathira Perera on global cancer surgery
Short-course radiotherapy for advanced rectal cancer
The crucial role of oncology nurses in cancer care
The effect of climate change on cancer control